Covalent (irreversible) Bruton’s tyrosine kinase (BTK) inhibitors bind to the C481 residue of BTK and block the ATP-binding pocket, thereby preventing catalytic activity. Despite excellent ...

Several poly (ADP-ribose) polymerase inhibitors (PARPi) have been approved by the US Food and Drug Administration (FDA) for treatment of patients with BRCA1 m and/or BRCA2 m across solid tumors, ...